A detailed history of Vanguard Group Inc transactions in Savara Inc stock. As of the latest transaction made, Vanguard Group Inc holds 7,944,011 shares of SVRA stock, worth $25.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,944,011
Previous 6,638,758 19.66%
Holding current value
$25.4 Million
Previous $26.8 Million 25.9%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.96 - $5.07 $5.17 Million - $6.62 Million
1,305,253 Added 19.66%
7,944,011 $33.7 Million
Q2 2024

Aug 13, 2024

BUY
$3.66 - $5.34 $2.11 Million - $3.07 Million
575,138 Added 9.49%
6,638,758 $26.8 Million
Q1 2024

May 10, 2024

BUY
$4.19 - $5.59 $622,939 - $831,082
148,673 Added 2.51%
6,063,620 $30.2 Million
Q4 2023

Feb 14, 2024

BUY
$3.18 - $4.9 $478,100 - $736,695
150,346 Added 2.61%
5,914,947 $27.8 Million
Q3 2023

Nov 14, 2023

BUY
$2.97 - $3.88 $2.34 Million - $3.06 Million
789,249 Added 15.86%
5,764,601 $21.8 Million
Q2 2023

Aug 14, 2023

BUY
$1.69 - $3.24 $420,267 - $805,719
248,679 Added 5.26%
4,975,352 $15.9 Million
Q1 2023

May 15, 2023

SELL
$1.6 - $2.82 $127,840 - $225,318
-79,900 Reduced 1.66%
4,726,673 $9.22 Million
Q4 2022

Feb 10, 2023

BUY
$1.11 - $1.64 $1,694 - $2,504
1,527 Added 0.03%
4,806,573 $7.45 Million
Q3 2022

Nov 14, 2022

SELL
$1.36 - $1.88 $651 - $900
-479 Reduced 0.01%
4,805,046 $7.45 Million
Q2 2022

Aug 12, 2022

SELL
$1.1 - $1.58 $15,068 - $21,644
-13,699 Reduced 0.28%
4,805,525 $7.3 Million
Q1 2022

May 13, 2022

SELL
$1.05 - $1.36 $21,800 - $28,236
-20,762 Reduced 0.43%
4,819,224 $6.31 Million
Q4 2021

Feb 14, 2022

BUY
$1.04 - $1.34 $361,648 - $465,970
347,739 Added 7.74%
4,839,986 $6 Million
Q2 2021

Aug 13, 2021

BUY
$1.51 - $2.29 $6.78 Million - $10.3 Million
4,492,247 New
4,492,247 $7.64 Million

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.